SunGlowInnovations

CDX-101

Clinical trials

Study design, outcomes and participation information for the planned Phase 1 study.

View ClinicalTrials.gov record NCT07911293

Research interest registration is open The study team will publish site and screening details when enrollment opens.

Participation options for patients outside China

U.S. trial site

U.S. site updates

U.S. patients can register their interest now. Once a U.S. study site opens enrollment, the site team will announce screening arrangements and assess eligibility under the applicable protocol.

U.S. study interest form
U.S. single-patient expanded access

Single-patient expanded access is a U.S. pathway for potential investigational treatment outside a clinical trial. For a non-emergency request, the treating physician contacts the sponsor to discuss availability for the individual patient and the next steps.

  1. Patient and treating physician discuss the request

    The physician reviews trial access, available alternatives, and whether the potential benefit justifies the risk for a patient with a serious or immediately life-threatening condition.

  2. Physician contacts the sponsor

    Ask whether CDX-101 can be supplied for this patient. If the sponsor agrees, request a Letter of Authorization (LOA) allowing FDA to reference IND 184255. The IND number alone does not authorize treatment.

  3. Physician submits the FDA request and arranges IRB review

    For a physician-sponsored non-emergency request, the physician files Form FDA 3926 and the LOA, if provided. The physician arranges Institutional Review Board review or eligible concurrence under the FDA procedure.

  4. Confirm all conditions before treatment

    For a non-emergency individual-patient IND, the FDA waiting period is generally 30 days after receipt unless FDA allows an earlier start. Before proceeding, the physician confirms the request can go ahead, completes applicable IRB requirements and obtains informed consent. The physician then monitors the patient and makes required reports.

Single-patient expanded access inquiry

Local simulation. Use fictional information and dummy files only. Nothing is submitted, saved or reviewed by a study team.

Anyone can complete this inquiry. Add the physician and clinical information if available.

Contact and case information

Acknowledgments

Signature of the person completing this form

China site pre-registration

Patients outside China who are interested in traveling to China can submit a pre-registration here. Beijing Hospital is the proposed China study site. The research team will announce international screening, visits, language support and costs when that pathway opens.

The China draft describes 1–10 eligible target lesions, each no larger than 10 cm, and allows other non-target lesions to be recorded. Screening is based on the applicable approved protocol and investigator review.

The China clinical trial is free of charge to participants. This covers study treatment, protocol-required tests and follow-up.

International patient coordination fee · USD 6,000 International patients using this pathway pay a separate fee for coordination services. The team will provide the fee details in writing before payment.

Pre-registration for the Intratumoral Chlorine Dioxide Ablation Trial at a Hospital in China

Local simulation. Use fictional information and dummy files only. Nothing is submitted, saved or reviewed by a study team.

Pre-registration helps the study team contact you and conduct a preliminary review. Pre-registration does not guarantee enrollment or constitute a medical commitment.

1. Basic information

2. Tumor information

Tumor locations (select all that apply)
The draft limits eligible target lesions. The investigator assesses target and non-target lesions separately.
The draft excludes intracranial lesions as treatment targets.
MRI may help assess a lesion. The draft describes ultrasound, CT or direct visualization for delivery.

3. Medical history and visit availability

Current treatments (select all that apply)
Travel planning only. The actual visit schedule depends on the approved protocol and investigator assessment.
4. Study acknowledgments

All eight items must be checked before you can submit.

5. Participation interest

Reasons for your interest (select all that apply)

6. Recent diagnostic reports

In a future authorized workflow this could include imaging (CT, MRI, PET-CT, ultrasound), pathology and other diagnostic reports. For this demo, select up to five dummy files. The site checks the count only.

7. Privacy acknowledgment and test signature

This demo holds information only while the form is open and clears it after a successful simulation. Any future real intake will need a separate privacy notice covering use, protection and deletion requests.

CDX-101 Phase 1 study

The planned Phase 1 study is prospective, open-label and single-arm, in adults with advanced extracranial solid tumors. The v3.0 protocol under the U.S. IND describes a safety lead-in followed by review by an independent data safety monitoring board and expansion to approximately 50 participants. The China protocol is managed separately.

Planned population

Adults with advanced extracranial solid tumors and safely accessible lesions. A multidisciplinary team would assess standard curative options, organ function and clinical status.

Primary endpoints

Dose-limiting toxicities, adverse events and serious adverse events. Containment measures include visible extra-lesional distribution, mandatory stops and non-target tissue injury.

Secondary endpoints

Lesion- and patient-level complete non-viable response (CNVR), extent of necrosis, local control and durability, RECIST 1.1, patient-reported outcomes, reaction products and hematologic measures.

Imaging and study site

Beijing Hospital is named as the proposed initial site. The study team will announce the enrollment process when the site opens. Imaging or direct visualization is used to monitor distribution in the proposed research.

Protocol v3.0 §§3–5, 7–10 · 2026-11-19

Participation process

  1. Review the study overview
  2. Check official recruitment updates
  3. Speak with an authorized study team when a site opens
  4. Review consent and any screening with the investigator
Research interest

Frequently asked questions

When will the study start?

The site accepts research interest registrations. The study team will announce the start date and screening process when enrollment opens.

How can I learn about participation?

When recruitment opens, investigators will assess suitability under the applicable ethics-approved protocol and formal consent process.

What happens after I submit the form?

The research team can review your inquiry and follow up using the contact information you provide if you agree to be contacted. Formal screening and enrollment follow the study’s separate process.

What comes after Phase 1, and what is the long-term treatment goal?

We plan to continue expanding clinical development beyond Phase 1 and ultimately complete a confirmatory trial. We expect image-guided intratumoral injection to remain the core approach. Later study protocols will reflect the safety and response findings from earlier studies.

In a planned study population whose identified tumors can all be treated safely under the protocol, our development goal across phases is a 95% patient-level complete response rate. The proposed approach is to treat all such lesions, with up to four injection sessions per lesion, aiming for the lesions to become undetectable on follow-up imaging. Complete response will be assessed at the patient level using the study’s prespecified criteria.